The Board Meeting of Bliss GVS Pharma Limited ( the Company ) was held today i.e. Tuesday, February 10, 2026, at the registered office has considered and approved the following matter(s) amongst others:1. Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025. A copy of unaudited Standalone and Consolidated Financial Results of the Company, along with the Limited Review Report of the Auditors of the Company for the quarter and nine months ended December 31, 2025, are enclosed herewith as 'Annexure-1 ; and 2. Declared the Interim dividend of 50% i.e. 0.50 paisa per equity share on face value of Re.1/- each for the financial year 2025-2026. The Interim Dividend shall be paid within 30 days from the date of its declaration.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Bliss GVS Pharma met on February 10, 2026, and approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with the auditors' limited review report. The Board also declared an interim dividend of 50%, i.e., Rs. 0.50 per equity share on a face value of Re. 1, for the financial year 2025-26. The interim dividend will be paid to shareholders within 30 days from the date of declaration.
The interim dividend of Rs. 0.50 per share signals a payout to shareholders and reflects the company's cash position, while the results approval is a routine regulatory disclosure without immediate stock-moving implications unless the numbers deviate sharply from expectations.